Literature DB >> 7989774

Differential gene expression for IL-1 receptor antagonist, IL-1, and TNF receptors and IL-1 and TNF synthesis may explain IL-1-induced resistance to infection.

M T Vogels1, E J Mensink, K Ye, O C Boerman, C M Verschueren, C A Dinarello, J W van der Meer.   

Abstract

IL-1 pretreatment prolongs survival in lethal infection in normal and in neutropenic mice. We investigated whether this protection occurs by interference with deleterious cytokine effects. The effect of IL-1 pretreatment on concentrations of IL-1 alpha, IL-1 beta, IL-6, and TNF-alpha circulating in vivo and the ex vivo cytokine production capacity of macrophages was assessed in uninfected, non-neutropenic and neutropenic Swiss mice, in Swiss mice infected with Klebsiella pneumoniae (non-neutropenic mice) or Pseudomonas aeruginosa (neutropenic mice), and in neutropenic C3H/HeN and C3H/HeJ mice infected with P. aeruginosa. In Swiss and C3H/HeN mice, IL-1 pretreatment enhanced survival and reduced circulating TNF-alpha and IL-6 as well as LPS-stimulated production of IL-1 alpha and TNF-alpha. In C3H/HeJ mice, a lack of IL-1-induced protection was associated with low cytokine concentrations and production. In contrast, up-regulation of mRNA for the IL-1 receptor antagonist (IL-1Ra) was observed in several organs of IL-1-pretreated mice, suggesting that IL-1Ra could attenuate deleterious IL-1 effects. In addition, IL-1 pretreatment down-regulated steady state mRNA for the type I IL-1R and the type I TNFR in several organs at the time of infection, suggesting desensitization of target cells as an additional mechanism of IL-1-induced protection. We conclude that the IL-1-induced protection is at least partially mediated by down-regulating cytokine production, and that the induction of IL-1Ra and the desensitization of target cells by receptor down-modulation may also contribute to this phenomenon.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7989774

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Randomized study of the benefits of preoperative corticosteroid administration on the postoperative morbidity and cytokine response in patients undergoing surgery for esophageal cancer.

Authors:  Nobuhiro Sato; Keisuke Koeda; Kenichiro Ikeda; Yusuke Kimura; Kiichi Aoki; Takeshi Iwaya; Yuji Akiyama; Kaoru Ishida; Kazuyoshi Saito; Shigeatsu Endo
Journal:  Ann Surg       Date:  2002-08       Impact factor: 12.969

2.  Regulation of brain interleukin-1 beta (IL-1 beta) system mRNAs in response to pathophysiological concentrations of IL-1 beta in the cerebrospinal fluid.

Authors:  S E Ilyin; G Sonti; D Gayle; C R Plata-Salamán
Journal:  J Mol Neurosci       Date:  1996       Impact factor: 3.444

Review 3.  Natural pathogens of laboratory mice, rats, and rabbits and their effects on research.

Authors:  D G Baker
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

Review 4.  Trends in immunotherapy of fungal infections.

Authors:  B J Kullberg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

5.  Toll-like receptor 4-deficient mice have reduced bone destruction following mixed anaerobic infection.

Authors:  L Hou; H Sasaki; P Stashenko
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

6.  Colonic explant production of IL-1and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD).

Authors:  S Dionne; I D D'Agata; J Hiscott; T Vanounou; E G Seidman
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

7.  Interleukin-1 (IL-1)-induced resistance to bacterial infection: role of the type I IL-1 receptor.

Authors:  M T Vogels; W M Eling; A Otten; J W van der Meer
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

8.  Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections.

Authors:  M G Netea; P N Demacker; B J Kullberg; O C Boerman; I Verschueren; A F Stalenhoef; J W van der Meer
Journal:  J Clin Invest       Date:  1996-03-15       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.